Treatment-related deaths and second cancer risk after autologous stem- cell transplantation for Hodgkin's disease

Blood

Volumn 92, Issue 6, 1998, Pages 1933-1940

  André, Marc ^b   Henry Amar, Michel ^b   Blaise, Didier ^b   Colombat, Philippe ^b   Fleury, Joël ^b   Milpied, Noël ^b   Cahn, Jean Yves ^b   Pico, José Luis ^b   Bastion, Yves ^b   Kuentz, Mathieu ^b   Nedellec, Gérard ^b   Attal, Michel ^b   Fermé, Christophe ^b   Gisselbrecht, Christian ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; SCHOOL CHILD; SECOND CANCER; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MECHLORETHAMINE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PREDNISONE; PROCARBAZINE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 0032530918     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstetn E, Phares JC, Jaffe ES, Urba WJ, DeVita VT: Conventionaldose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210, 1992
2. Jagannath S, Dicke K, Armitage JO, Cabanillas FF, Horwitz LJ, Vellekop L, Zander AR, Spitzer G: High-dose Cyclophosphamide, Carmustine and Etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease, Ann Intern Med 104:163, 1986
3. Gribben JG, Linch DC, Singer AK, McMillan AK, Jarrett M, Goldstone AH: Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 73:340, 1989
4. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G, Meloni G, Cimino G, Mangoni L, Cosser P, Getto GL, Cimino R, Allessandrino EP, Santini E, Tura S, Mandelli F, Rizzoli V, Bernasconi C, Marmont AM: High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 6:1411, 1988
5. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Vaughan Hudson G: Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BLNI randomised trial. Lancet 341:1051, 1993
6. Carella AM, Carier P, Congiu A, Occhini D, Nati S, Santini G, Giordano PD, Bacigalupo A, Damasio E. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 8:31, 1991
7. Fleury J, Legros M, Colombat Ph, Cure H, Travade p, Tortochaux J, Diomet C, Chollet P, Lemassier C, Lamagnere JP, Blaise D, Viens P, Maraninchi D, Plagne R: High-dose chemotherapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma 20:259, 1996
8. Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, Yahalom J, Clarckson BD: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate dose radiation therapy. J Clin Oncol 8:1173, 1990
9. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenburger DJ, Kessinger A, Armitage JO: Incidence and characterisation of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527, 1994
10. Stone RM, Neuberg D, Soiffier R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM: Myelodysplastic syndrome as late complication following autologous bone marrow transplantation for non-Hodgkin Lymphoma. J Clin Oncol 12:2535, 1994
11. Crosby WH: Acute granulocytic leukemia, a complication of therapy in Hodgkin's disease? Clin Res 12:1103, 1969
12. Henry-Amar M, Dietrich PY: Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 7:369, 1993
13. Henry-Amar M, Aeppli DM, Anderson J: Workshop statistical report. Part IX: Study of second cancer risk, in Somers R, Henry-Amar M, Meerwaldt JH, Carde P (eds). Treatment strategy in Hodgkin's disease. Colloque Inserm, vol 196. London, Paris, Inserm/John Libbey Eurotext, 1990, p 355
14. Henry-Amar M, Pellae-Cosset B, Bayle-Weisgerber C: Risk of secondary acute leukemia and pre-leukemia after Hodgkin's disease. The Institut Gustave-Roussy experience, in Dhiel V, Pfreundschuh M, Loeffler M (eds): New Aspects in the Diagnosis and Treatment of Hodgkin's Disease. Recent Results in Cancer Research, vol 117. Berlin, Germany, Springer-Verlag, 1989, p 270
15. Van Leeuwen FE, Chorus AMJ, Van den Belt-Dusebout AW, Hagenbeek A, Nayon R, van Kerkof EHM, Pinedo HM, Somers R: Leukemia risk following Hodgkin's disease relative to cumulative dose of alkylating agent, treatment with Teniposide combination, number of episode of chemotherapy and bone marrow damage. J Clin Oncol 12:1063, 1994
16. World Health Organisation. Manual of the International statistical classification of disease, injuries and causes of death: Based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly, Vol I. Geneva, Switzerland, World Health Organisation, 1977
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
18. Cox DR: Regression models and life-tables. J R Stat Soc 33:187, 1972
19. Wartelle M, Kramar A, Jan P, Kruger D: "Pigas" : An interactive statistical database management system, in Hammond R, McCarthy JL (eds): Proceedings of Second International Workshop on Statistical Database Management, Los Altos, CA. Springfield, IL, National Technical Information Service, US Department of Commerce, 1983, p 124
20. Stata reference Manual: Release 3 (ed 5), Santa Monica, CA, Computing Resource Center, 1992
21. Tucker MA, Meadows AT, Boice JD, Stovall M, Oberlin O, Stone BJ, Birch J, Voule PA, Hoover RN, Fraumeni JF: Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78:459, 1987
22. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA: Risk of second cancer after treatment for Hodgkin's disease. N Engl J Med 318:76, 1988
23. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G: Increased risk of acute leukemia following extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8:1148, 1990
24. Van Leeuwen FE, Somers R, Hart AAM: Splenectomy in Hodgkin's disease and second leukemia. Lancet 2:210, 1987 (letter)
25. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Ann Oncol 3:117, 1992
26. Reece DE; Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingmann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Philips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatine and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination therapy. Blood 83:1193, 1994
27. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DP, Somlo G, Margolin KA, Sniecinski I, Dagis AC, Niland J, Pezner R, Forman SJ: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381, 1995
28. Coltman CA, Dixon DO: Second malignancies complicating Hodgkin's disease: A Southwest Oncology Study Group 10-year follow-up. Cancer Treat Res 66:1023, 1982
29. Dietrich PY, Henry-Amar M, Cosset JM, Bodis S, Bosq J, Hayat M: Second primary cancers in patients continuously disease-free from Hodgkin's disease: A protective role for the spleen. Blood 84:1209, 1994
30. Bhatia S, Ramsay NK, Steinbuch M, Dussenberg KE, Shapiro RS, Weisdorf DS, Robinson LL, Miller JS, Neglia JP: Malignant neoplasm following bone marrow transplantation. Blood 87:3633, 1996
31. Traweek ST, Slovak ML, Nademanee AP, Brygnes RK, Niland JC, Forman JJ: Clonal karyotipic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin lymphoma. Blood 84:957, 1994
32. Guillaume Th, Sekhavat M, Rubinstein DB, Hamdam O, Leblanc P, Symann M: Defective cytokine production following autologous stem cell transplantation for solid tumors and hematologic malignancies regardless of bone marrow or peripheral origin and lack of evidence for a role for interleukin-10 in delayed immune reconstitution. Cancer Res 54:3800, 1994
33. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347:353, 1996
34. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:1846, 1993
35. Brice P, Marolleau JP, Pautier P, Makki J, Cazals D, Dombret H, D'Agay MF, Benbunnan M, Gisselbrecht C: Hematological recovery and survival of lymphoma patients after autologous stem cell transplantation: Comparison of bone marrow and peripheral blood progenitor cell. Leuk Lymphoma 22:449, 1996
36. Boivin JF, Hutchison GB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CT, Fuller LM, Mauch P, Ultmann J. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87:732, 1995